Advanced Search

Journal of Traditional Chinese Medicine >

2022 , Vol. 42 >Issue 6: 988 - 996

DOI: https://doi.org/10.19852/j.cnki.jtcm.20220902.002

Research Articles

Effectiveness of Jiedu granule (解毒颗粒) on gut microbiota in patients with advanced hepatocellular carcinoma: a randomized controlled trial

  • Yifu FAN ,
  • Hetong ZHAO ,
  • Yani ZHANG ,
  • Zifei Yani ,
  • Juan DU ,
  • Changquan LING
Expand
  • School of Traditional Chinese Medicine, Navy Medical University, Shanghai 200433, China
Prof. Du Juan, School of Traditional Chinese Medicine, Navy Medical University, Shanghai 200433, China. dujuan714@163.com, Telephone: +86-21-81873143; +86-21-81873145
Prof. LING Changquan, School of Traditional Chinese Medicine, Navy Medical University, Shanghai 200433, China. changquanling@smmu.edu.cn;

Received date: 2021-10-18

  Accepted date: 2022-01-05

  Online published: 2022-09-02

Supported by

Value of Heat Clearing and Detoxification in the Treatment of Primary Liver Cancer from the Perspective of Tumor Inflammatory Microenvironment(81430101);Explore the Mechanism of Sanshimao Granule on Anti-recurrence and Metastasis of Liver Cancer from the Perspective of Sec62 Regulating ER Stress(81473487);Molecular Mechanism of Aconitum Decoction in Interfering with Immune Escape of Hepatocellular Carcinoma via Regulating the Spectrum Shift of NK Cell Receptor/Ligand(81774244)

Fold

Abstract

OBJECTIVE: To observe whether Jiedu granule (解毒颗粒, JDG) modulates the composition of the gut microbiota during advanced hepatocellular carcinoma (HCC).

METHODS: A randomized controlled trial was conducted. Sixty-two advanced HCC participants were randomly allocated to receive JDG or placebo. The median overall survival (OS) times of patients and the variation of relative abundance of bacteria over time were used as main outcome measures.

RESULTS: Patients who received JDG demonstrated significantly longer median OS times compared with the placebo group. Pyrosequencing of the V3 regions of 16S rRNA genes revealed a dose dependent deviation of gut microbiota in response to JDG treatment. Redundancy analysis identified Clostridium XI and Peptostre-ptococcaceae which related to the onset of liver cancer disappeared after 1-month and 2-month JDG treatment, while in control group, no significant changes of these two bacteria were found. The variation tendency of relative abundance of Bacteroides (essential in immunoblocking therapy of tumor) in JDG group was not obvious while in control group, it was decreased significantly with time. The relative abundance of Roseburia (correlated with the occurrence of liver cancer) was increased in JDG group and was decreased in control group over time.

CONCLUSION: Changes in the gut microbiota may be associated with the efficiency of JDG on survival period of advanced HCC patients.

Trial registration：Chinese Clinical TRIAL Registry ChiCTR-OOC-16008002.

Key words： microbiota; carcinoma, hepatocellular; survival; randomized controlled trial; Jiedu granule

Cite this article

Yifu FAN , Hetong ZHAO , Yani ZHANG , Zifei Yani , Juan DU , Changquan LING . Effectiveness of Jiedu granule (解毒颗粒) on gut microbiota in patients with advanced hepatocellular carcinoma: a randomized controlled trial[J]. Journal of Traditional Chinese Medicine, 2022 , 42(6) : 988 -996 . DOI: 10.19852/j.cnki.jtcm.20220902.002

References

[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016; 66: 115-32.
[2] Zheng R, Qu C, Zhang S, et al. Liver cancer incidence and mortality in China: temporal trends and projections to 2030. Chin J Cancer Res 2018; 30: 571-9.
[3] Li N, Zhu Y. Targeting liver cancer stem cells for the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol 2019; 12: 1756284818821560.
[4] Caussy C, Tripathi A, Humphrey G, et al. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nat Commun 2019; 10: 1406.
[5] Loomba R, Seguritan V, Li W, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 2019; 30: 607.
[6] Oh TG, Kim SM, Caussy C, et al. A universal gut-microbiome-derived signature predicts cirrhosis. Cell Metab 2020; 32: 878-88.
[7] Loomba R, Seguritan V, Li W, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 2017; 25: 1054-62.
[8] Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology 2019; 69: 107-20.
[9] Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut 2019; 68: 1014-23.
[10] Loo TM, Kamachi F, Watanabe Y, et al. Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity. Cancer Discov 2017; 7: 522-38.
[11] Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013; 499: 97-101.
[12] Ma C, Han M, Heinrich B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 2018; 360: eaan5931.
[13] Gao L, Wang KX, Zhou YZ, Fang JS, Qin XM, Du GH. Uncovering the anticancer mechanism of compound Kushen Injection against HCC by integrating quantitative analysis, network analysis and experimental validation. Sci Rep 2018; 8: 624.
[14] Bao Y, Wang S, Yang X, Li T, Xia Y, Meng X. Metabolomic study of the intervention effects of Shuihonghuazi formula, a traditional Chinese medicinal formulae, on hepatocellular carcinoma (HCC) rats using performance HPLC/ESI-TOF-MS. J Ethnopharmacol 2017; 198: 468-78.
[15] Abou-Hashem MMM, Abo-elmatty DM, Mesbah NM, El-Mawgoud AMA. Induction of sub-G0 arrest and apoptosis by seed extract of Moringa peregrina (Forssk.) Fiori in cervical and prostate cancer cell lines. J Integr Med 2019; 17: 410-22.
[16] Oliveira CR, Spindola DG, Garcia DM, et al. Medicinal properties of Angelica archangelica root extract: cytotoxicity in breast cancer cells and its protective effects against in vivo tumor development. J Integr Med 2019; 17: 132-40.
[17] Ministry of Health of the People’s Republic of China. Standards for diagnosis and treatment of primary liver cancer. Lin Chuang Gan Dan Bing Za Zhi 2011; 27: 1141-56.
[18] Yu Y, Lang Q, Chen Z, et al. The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study. Cancer 2009; 115: 5132-8.
[19] Zhai XF, Chen Z, Li B, et al. Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial. J Integr Med 2013; 11: 90-100.
[20] Ticinesi A, Lauretani F, Tana C, Nouvenne A, Ridolo E, Meschi T. Exercise and immune system as modulators of intestinal microbiome implications for the gut-muscle axis hypothesis. Exerc Immunol Rev 2019; 25: 84-95.
[21] Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol 2017; 14: 527-39.
[22] Wan MLY, El-Nezami H. Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy. Hepatobiliary Surg Nutr 2018; 7: 11-20.
[23] Ezzaidi N, Zhang X, Coker OO, Yu J. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer. Cancer Lett 2019; 459: 186-91.
[24] Xu J, Chen HB, Li SL. Understanding the molecular mechanisms of the interplay between herbal medicines and gut microbiota. Med Res Rev 2017; 37: 1140-85.
[25] Bureau of Medical Administration, National Health and Family Planning Comission of the People’s Republic of China. Standards for diagnosis and treatment of primary liver cancer. Zhong Hua Gan Zang Bing Za Zhi 2017; 25: 886-95.
[26] Doig GS, Simpson F. Randomization and allocation concealment: a practical guide for researchers. J Crit Care 2005; 20: 187-91.
[27] Amato KR, Yeoman CJ, Kent A, et al. Habitat degradation impacts black howler monkey (Alouatta pigra) gastrointestinal microbiomes. ISME J 2013; 7: 1344-53.
[28] Ren W, Xun Z, Wang Z, et al. Tongue coating and the salivary microbial communities vary in children with halitosis. Sci Rep 2016; 6: 24481.
[29] Xu Y, Wang XS, Chen Y, Shi Q, Chen TH, Li P. A phase II randomized controlled trial of Renshen Yangrong Tang herbal extract granules for fatigue reduction in cancer survivors. J Pain Symptom Manage 2020; 59: 966-73.
[30] Pan B, Zang J, He J, Wang Z, Liu L. Add-On therapy with Chinese herb medicine Bo-Er-Ning capsule (BENC) improves outcomes of gastric cancer patients: a randomized clinical trial followed with bioinformatics-assisted mechanism study. Am J Cancer Res 2018; 8: 1090-105.
[31] Bhargava A, Pathak N, Seshadri S, et al. Pre-clinical validation of mito-targeted nano-engineered flavonoids isolated from Selaginella bryopteris (Sanjeevani) as a novel cancer prevention strategy. Anticancer Agents Med Chem 2018; 18: 1860-74.
[32] Newman TM, Vitolins MZ, Cook KL. From the table to the tumor: the role of mediterranean and Western dietary patterns in shifting microbial-mediated signaling to impact breast cancer risk. Nutrients 2019; 11: E2565.
[33] Liu D, Jiang XY, Zhou LS. Enriched environment on the intestinal mucosal barrier and brain-gut axis in rats with colorectal cancer. Exp Biol Med (Maywood) 2018; 243: 1185-98.
[34] Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013; 499: 97-101.
[35] Jung MJ, Lee J, Shin NR, et al. Chronic repression of mTOR complex 2 induces changes in the gut microbiota of diet-induced obese mice. Sci Rep 2016; 6: 30887.
[36] Centuori SM, Martinez JD. Differential regulation of EGFR-MAPK signaling by deoxycholic acid (DCA) and ursodeoxycholic acid (UDCA) in colon cancer. Dig Dis Sci 2014; 59: 2367-80.
[37] Ahn J, Sinha R, Pei Z, et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst 2013; 105: 1907-11.
[38] Galperin MY, Brover V, Tolstoy I, Yutin N. Phylogenomic analysis of the family Peptostreptococcaceae (Clostridium cluster XI) and proposal for reclassification of Clostridium litorale (Fendrich et al. 1991) and Eubacterium acidaminophilum (Zindel et al. 1989) as Peptoclostridium litorale gen. nov. comb. nov. and Peptoclostridium acidaminophilum comb. nov. Int J Syst Evol Microbiol 2016; 66: 5506-13.
[39] Sobhani I, Tap J, Roudot-Thoraval F, et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 2011; 6: e16393.
[40] Akin H, Tözün N. Diet, microbiota, and colorectal cancer. J Clin Gastroenterol 2014; 48: S67-9.
[41] Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350: 1079-84.
[42] Sivan A, Corrales L, Hubert N, et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti PD-L1 efficacy. Science 2015; 350: 1084-9.
[43] Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014; 63: 1275-83.
[44] Jiang S, Xie S, Lv D, et al. A reduction in the butyrate producing species Roseburia spp. and Faecalibacterium prausnitzii is associated with chronic kidney disease progression. Antonie Van Leeuwenhoek 2016; 109: 1389-96.
[45] Wu YN, Zhang L, Chen T, Li X, He LH, Liu GX. Granulocyte-macrophage colony-stimulating factor protects mice against hepatocellular carcinoma by ameliorating intestinal dysbiosis and attenuating inflammation. World J Gastroenterol 2020; 26: 5420-36.
[46] Mondot S, Lepage P, Seksik P, et al. Structural robustness of the gut mucosal microbiota is associated with Crohn’s disease remission after surgery. Gut 2016; 65: 954-62.
[47] Vacca M, Celano G, Calabrese FM, Portincasa P, Gobbetti M, De Angelis M. The controversial role of human gut Lachnospiraceae. Microorganisms 2020; 8: 573.
[48] Meehan CJ, Beiko RG. A phylogenomic view of ecological specialization in the Lachnospiraceae, a family of digestive tract-associated bacteria. Genome Biol Evol 2014; 6: 703-13.
[49] Dong J, Li W, Dong A, et al. Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5. Med Oncol 2014; 31: 95.
[50] Fan YF, Zhang HQ, Yang GL, Wu C, Guo YY, Ling CQ. China’s cancer patients’ perceptions, attitudes and participation in clinical trials of complementary and alternative medicine: a multi-center cross-sectional study. Eur J Integr Med 2018; 19: 115-20.
Options
Outlines

/

〈 〉